Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers
…, K Sano, N Nagata, T Suzuki, Y Wakimoto… - Journal of Infection and …, 2021 - Elsevier
Introduction Information on the effectiveness of personal protective equipment (PPE) for
preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among …
preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among …
[HTML][HTML] Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
…, A Otani, M Yamashita, Y Wakimoto… - International Journal of …, 2023 - Elsevier
Objectives To evaluate the efficacy and safety of nafamostat combined with favipiravir for
the treatment of COVID-19. Methods We conducted a multicenter, randomized, single-blind, …
the treatment of COVID-19. Methods We conducted a multicenter, randomized, single-blind, …
[HTML][HTML] Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate
…, K Okamoto, M Ikeda, A Otani, Y Wakimoto… - Journal of Thrombosis …, 2021 - Springer
Critical illnesses associated with coronavirus disease 2019 (COVID-19) are attributable to a
hypercoagulable status. There is limited knowledge regarding the dynamic changes in …
hypercoagulable status. There is limited knowledge regarding the dynamic changes in …
[HTML][HTML] Evaluation of coronavirus disease 2019 severity using urine biomarkers
…, A Okuhama, K Kanda, Y Wakimoto… - Critical Care …, 2020 - journals.lww.com
Interventions: Not applicable. Measurements and Main Results: This is single-center study,
national center hospital designated for infectious disease. Fifty-eight patients who tested …
national center hospital designated for infectious disease. Fifty-eight patients who tested …
SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine
…, A Okuhama, K Kanda, Y Wakimoto… - Global Health & …, 2020 - jstage.jst.go.jp
Due to the significant spread of a new type of coronavirus (SARS-CoV-2) infection (COVID-19)
in China, the Chinese government blockaded several cities in Hubei Province. Japanese …
in China, the Chinese government blockaded several cities in Hubei Province. Japanese …
The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in …
…, T Shinohara, M Yamashita, Y Wakimoto… - Human Vaccines & …, 2022 - Taylor & Francis
Adverse reactions after vaccination with COVID-19 mRNA vaccines are common; however,
the association between adverse reactions and humoral responses is uncertain. To …
the association between adverse reactions and humoral responses is uncertain. To …
Acute pancreatitis during COVID-19 pneumonia
T Shinohara, A Otani, M Yamashita, Y Wakimoto… - Pancreas, 2020 - journals.lww.com
To the Editor: Novel coronavirus disease (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has been affecting millions of people globally. …
syndrome coronavirus 2 (SARS-CoV-2), has been affecting millions of people globally. …
[HTML][HTML] Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA …
…, M Saito, T Shinohara, M Yamashita, Y Wakimoto… - Scientific Reports, 2023 - nature.com
Several clinical trials have shown that the humoral response produced by anti-spike
antibodies elicited by coronavirus disease 2019 (COVID-19) vaccines gradually declines. The …
antibodies elicited by coronavirus disease 2019 (COVID-19) vaccines gradually declines. The …
[HTML][HTML] Environmental surface and air contamination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patient rooms by disease severity
…, Y Sugiki, A Okuhama, K Kanda, Y Wakimoto… - Infection Prevention in …, 2020 - Elsevier
Background The coronavirus disease 2019 (COVID-19) continues to spread around the
world. In addition to community-acquired infections, nosocomial infections are also a major …
world. In addition to community-acquired infections, nosocomial infections are also a major …
Guanfacine extended release for the reduction of aggression, attention-deficit/hyperactivity disorder symptoms, and self-injurious behavior in Prader-Willi syndrome …
D Singh, Y Wakimoto, C Filangieri… - Journal of child and …, 2019 - liebertpub.com
Objective: To examine the role of Guanfacine Extended Release (GXR) in the management
of behavioral disturbances in patients with Prader-Willi Syndrome (PWS). Methods: Twenty …
of behavioral disturbances in patients with Prader-Willi Syndrome (PWS). Methods: Twenty …